Fig. 4: PDGFRA antagonist suppresses CHSY1-mediated malignant growth.
From: Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability
a Effects of crenolanib, a PDGFRA inhibitor, on CHSY1-enhanced cell viability. GL261 transfectants were treated with solvent (0.005% of ethanol) or crenolanib (0.5 μM) and then analyzed by CCK8 assays at 72 h. Data are represented as means ± SD from three independent experiments. **P < 0.01, ***P < 0.001. b Effects of PDGFRA inhibitor on anchorage-dependent colony formation. Results were presented as means ± SD from three independent experiments. Representative images were shown at the bottom. ***P < 0.001. c Survival analysis of crenolanib treatment in an orthotopic murine model of GL261 glioma. Mock and CHSY1-overexpressing transfecants were implanted into C57BL/6 mice. The next day post tumor implant, mice were treated with 15 mg/kg of crenolanib (Cre) via daily intraperitoneal injection for 7 days. Equivalent 5% of glycerol formal (Gly) was taken as solvent control. Survival was assessed via Kaplan–Meir survival curves. **P < 0.01 (CHSY1-Gly vs. CHSY1-Cre). #P < 0.05 (Mock-Cre vs. CHSY1-Cre). Median survival time (MS) of each group is shown at the right.
